Further discussion on the antiviral treatment of chronic hepatitis B patients with indeterminate phase
10.3969/j.issn.1001-5256.2023.10.001
- VernacularTitle:不确定期慢性乙型肝炎抗病毒治疗再探讨
- Author:
Hui ZHUANG
1
Author Information
1. Department of Microbiology and Center of Infectious Diseases， Peking University Health Science Center， Beijing 100191， China
- Publication Type:Journal Article
- Keywords:
Hepatitis B Virus;
Hepatitis B， Chronic;
Indeterminate Phase;
Carcinoma， Hepatocellular;
Therapeutics
- From:
Journal of Clinical Hepatology
2023;39(10):2273-2276
- CountryChina
- Language:Chinese
-
Abstract:
This paper discusses further on the antiviral treatment of chronic hepatitis B patients with indeterminate phase. These patients have a high proportion of significant necroinflammation and fibrosis in the liver， and a higher risk of disease progression compared with those with true HBeAg－positive chronic hepatitis B virus （HBV） infection （formerly called the immune tolerance phase） or HBeAg－negative chronic HBV infection （formerly called the immune control phase）. Antiviral therapy may reduce the risk of HBV－related hepatocellular carcinoma in chronic hepatitis B patients with indeterminate phase.
